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METHOD OF INHIBITING BINDING 
ACTIVITY OF IMMUNOGLOBULINS 
This is a continuation-in-part of US. patent application 
Ser. No. 08/250,245 noW abandoned, ?led May 27, 1994. 
TECHNICAL FIELD 
The present invention relates generally to the ?eld of 
biotechnology and, particularly, to a method for inhibiting 
the binding activity of immunoglobulins With immunogens, 
a method for inhibiting culture agglutination and the actual 
inhibitors. 
BACKGROUND OF THE INVENTION 
Many forms of immune proteins eXist in mammals includ 
ing humans, and other classes of animals having immune 
systems. It is generally believed that the immune proteins 
IgM and IgG are the most important proteins that provide 
protection against microbial invasion of mammals. IgM is 
similar to IgG but is composed of ?ve IgG-like molecules in 
a pentamer arrangement. The immunoglobulins IgM and 
IgG are circulated in the blood to combat invasion by foreign 
matter, mainly bacteria and are transferred to milk to estab 
lish immunity in nursing offspring. 
Scienti?c literature suggests that the immune proteins 
IgM and IgG interact When a binding site on the variable 
regions of the light and heavy chains (see FIG. 1) attaches 
to an antigenic site or to a complimentary binding site on the 
tail of the heavy chain (Fc fraction) of another IgM or IgG 
molecule. Many researchers believe that IgM and IgG lose 
their interactive ability When the heavy chains are removed 
from the Fab fractions. Our Work in the development of the 
present invention, hoWever, indicates that the carbohydrate 
moieties or constant regions on both the light and heavy 
chains of immune proteins are capable of interacting With 
antigenic sites and/or bridging compounds thereby causing 
immune reactions and agglutination. Thus, it should be 
appreciated, that simple cleavage of the Fab fraction is not 
effective to inhibit immune reactions. Accordingly, a neW 
method must be developed to achieve this end. 
SUMMARY OF THE INVENTION 
Accordingly, it is a primary object of the present invention 
to provide a method for inhibiting the binding activity of 
immunoglobulins With immunogens. Such a method has a 
number of bene?cial applications including, but not limited 
to, inhibiting culture agglutination in a fermentation medium 
and blocking selected antigenic sites so as to prevent prob 
lematic immune reactions in the health care ?eld. 
Yet another object of the present invention is to provide a 
method for inhibiting culture agglutination in a fermentation 
medium Wherein agglutination of the microorganisms 
responsible for fermentation is substantially prevented. Such 
a method alloWs, for example, more ef?cient production of 
a more consistent and higher quality fermentation product 
(eg cheddar cheese, cottage cheese). 
Still another object of the present invention is to provide 
a method for inhibiting the binding activity of mammalian 
immunoglobulins and in particular IgA, IgG and IgM in a 
biologically safe and effective manner. Such an approach 
may be utiliZed to limit or prevent immune reactions and 
prevent infection and, accordingly, are bene?cial for a 
number of uses in the care and treatment of patients suffering 
from a number maladies. 
Yet another object of the present invention is to provide 
inhibitors of the binding activity of immunoglobulins 
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including mammalian immunoglobulins and particularly 
IgA, IgG and IgM. This is accomplished through the utili 
Zation of corresponding immunoglobulins hydrolyZed With 
plant proteases to provide peptides having a molecular 
Weight of less than 10,000 Daltons and preferably of about 
1,000 Daltons. 
Additional objects, advantages and other novel features of 
the invention Will be set forth in part in the description that 
folloWs and in part Will become apparent to those skilled in 
the art upon examination of the folloWing or may be learned 
With the practice of the invention. The objects and advan 
tages of the invention may be realiZed and obtained by 
means of the instrumentalities and combinations particularly 
pointed out in the appended claims. 
To achieve the foregoing and other objects, and in accor 
dance With the purposes of the present invention as 
described herein, an improved method is provided for inhib 
iting the binding activity of immunoglobulins With immu 
nogens. The method is particularly adapted for utiliZation in 
inhibiting the binding activity of mammalian immunogens 
including, speci?cally, IgA, IgG and IgM immune proteins. 
The method broadly includes the initial step of treating a 
source of immunoglobulins With an enZyme that hydroliZes 
the immunoglobulins into immunoreactive peptides having 
a molecular Weight of less than 10,000 Daltons. Preferably, 
the enZyme is a plant protease that cleaves the 
immunoglobulins, IgA, IgG and IgM, above the second 
disul?de bond (see FIG. 1). This results in the liberation of 
tWo Fab fractions. The enZymes papain, ?cin and bromelain 
are particularly useful for this purpose. 
In addition to cleaving the immunogens IgA, IgG and IgM 
above the second disul?de bond, the hydrolysis is continued 
for an additional period of time to clip and remove the 
carbohydrate moiety or constant regions from the variable 
regions so as to provide a peptide fraction having a molecu 
lar Weight of less than 10,000 Daltons. This may be accom 
plished through ultra?ltering the source of immunoglobulins 
as they are hydroliZed With the enZyme. A dia?ltration 
technique may be utiliZed so that the smaller peptide frac 
tions produced as a result of hydrolysis (i.e. those under 
10,000 Daltons) pass as permeate through a polysulfone or 
other membrane having a molecular Weight cut off of 10,000 
Daltons. Speci?cally, to achieve this end, hydrolysis pref 
erably is completed at a temperature betWeen 30—50° C. for 
a period of at least tWo hours. As permeate is removed from 
the source of immunoglobulins undergoing hydrolysis a 
buffer of equivalent volume may be added. 
The permeate, consisting of peptides of a molecular 
Weight of less than 10,000 Daltons and preferably approxi 
mately 1,000 Daltons is then collected. FolloWing collecting 
is the reacting of immunogens With the peptides so as to bind 
and block antigenic sites on the immunogens. Then folloWs 
the introducing of the peptide bound and blocked immuno 
gens into the mammal. Advantageously, the bound and 
blocked antigenic sites on the immunogens make the immu 
nogens substantially “invisible” to the immune system of the 
mammal thereby preventing undesired and problematic 
immune reactions from occurring. 
Such an approach has a number of applications including, 
speci?c use in the arti?cial insemination of mammals 
including humans and other animals. Speci?cally, the sperm 
cells to be inseminated are reacted With the peptide so as to 
bind and block the antigenic sites or determinants on the 
sperm cells. When subsequently inseminated into a 
recipient, the immune reaction of the recipient is reduced 
and/or substantially eliminated, and accordingly, the aggre 
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gation of sperm cells is virtually prevented. Thus, the sperm 
cells remain free to reach the ovum for purposes of fertili 
Zation. 
In accordance With yet another aspect of the present 
invention, a method for inhibiting culture agglutination in a 
fermentation medium including immunogens is provided. 
As before, this method includes an initial step of treating a 
source of immunoglobulins With an enZyme such as a plant 
protease to hydroliZe the immunoglobulins into peptides 
having a molecular Weight of less than 10,000 Daltons and 
preferably, approximately 1,000 Daltons. Speci?cally, as 
previously described these peptides are produced utiliZing 
ultra?ltration and dia?ltration techniques. Preferably, 
papain, ?cin and/or bromelain is used as the enZyme. 
The immunoglobulins may be obtained from a number of 
sources including, but not limited to, raW Whey, dry Whey, 
Whey protein isolates, non-fat-dried milk, blood serum pro 
tein isolates, puri?ed immunogen preparations and mixtures 
thereof. 
FolloWing hydrolysis is the collecting of the peptides 
produced as a result of the treatment of the immunoglobulins 
With papain, ?cin and/or bromelain and in accordance With 
the ultra?ltration and dia?ltration techniques. Speci?cally, 
the resulting peptides present in the permeate may be 
concentrated utiliZing reverse osmosis or evaporation and 
then dried using freeZe drying, spray drying or vacuum 
drying techniques. These dried preparations can then be 
formulated into existing culture media preparations. 
The peptides in these culture media preparations are then 
utiliZed by inoculating a groWth media for microorganisms, 
useful in fermenting the fermentation medium, With the 
peptides. Next is the groWing of the microorganisms in the 
inoculated groWth media Whereby the peptides bind anti 
genic sites on the microorganisms. This is then folloWed by 
adding the microorganisms groWn in the inoculated groWth 
media to the fermentation medium Whereby the peptide 
bound antigenic sites on the microorganisms block the 
immunoglobulins in the fermentation medium from binding 
those antigenic sites and thereby causing agglutination of the 
microorganisms. 
Such a method is particularly useful in the production of 
cottage, cheddar and other cheeses Wherein agglutination is 
a signi?cant problem leading to revenue loss. Speci?cally, 
agglutination results in uneven distribution of starter culture 
throughout the milk and uneven acid production in the 
cheese vat. Grainy, shattered curd, sediment formation and 
sloW acid production are all problems that directly relate to 
agglutination of lactic acid starter strains. Accordingly, 
direct consequences of agglutination are inconsistent prod 
uct quality and yield losses Which both lead to decreased 
pro?ts. Accordingly, as the present invention addresses and 
largely relieves the agglutination problem, it represents a 
signi?cant advance in the art. 
In accordance With still another aspect of the present 
invention, an inhibitor is provided for inhibiting the binding 
activity of immunoglobulins and particularly mammalian 
immunoglobulins including IgA, IgG and IgM. Speci?cally, 
the inhibitor is derived from a source of immunoglobulins 
hydroliZed With a plant protease such as papain, ?cin and/or 
bromelain and then ultra?ltered With or Without dia?ltering 
to provide peptides having a molecular Weight of less than 
10,000 Daltons and preferably approximately 1,000 Daltons. 
Such an inhibitor Will have a number of unique biotechno 
logical applications such as in the health care ?eld Where it 
is particularly desirable to block problematic immune reac 
tions. 
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Still other objects of the present invention Will become 
apparent to those skilled in this art from the folloWing 
description Wherein there is shoWn and described a preferred 
embodiment of this invention, simply by Way of illustration 
of one of the modes best suited to carry out the invention. As 
it Will be realiZed, the invention is capable of other different 
embodiments and its several details are capable of modi? 
cation in various, obvious aspects all Without departing from 
the invention. Accordingly, the draWings and descriptions 
Will be regarded as illustrative in nature and not as restric 
tive. 
BRIEF DESCRIPTION OF THE DRAWING 
The accompanying draWing incorporated in and forming 
a part of this speci?cation, illustrates several aspects of the 
present invention, and together With the description serves to 
explain the principles of the invention. In the draWing: 
FIG. 1 is a schematical representation of an IgG molecule; 
FIG. 2 graphically shoWs the rate of top and bottom pH 
decrease of OS culture; 
FIG. 3 graphically shoWs the rate of top and bottom pH 
decrease of M30 culture; 
FIG. 4 graphically shoWs the rate of top and bottom pH 
decrease of M37 culture; 
FIG. 5 is a plot of the pH at the top of the skim milk 
column after addition of immunoglobulin (IgG), ?cin 
derived peptides, papain derived peptides and bromelain 
derived peptides per example 8; and 
FIG. 6 graphically shoWs free sWimming sperm cells in 
control and papain derived peptide treated spermatoZoa 
samples per Example 10. 
Reference Will noW be made in detail to the present 
preferred embodiment of the invention, an example of Which 
is illustrated in the accompanying draWing. 
DETAILED DESCRIPTION OF THE 
INVENTION 
A method for inhibiting the binding activity of immuno 
globulins and, particularly mammalian immunoglobulins 
IgA, IgM and IgG With an immunogen Will noW be 
described in detail. The method includes the initial step of 
treating mammalian immunoglobulins including IgA, IgG 
and IgM With an enZyme that hydroliZes the immunoglo 
bulins into immunoreactive peptides having a molecular 
Weight of less than 10,000 Daltons. Any source of immu 
noglobulins may be utiliZed including, for example, raW 
Whey, dry Whey, Whey protein isolates, non-fat-dried milk, 
blood serum protein isolates, pure fat immune protein prepa 
rations and mixtures thereof. It should be appreciated, 
hoWever, that this list is not exclusive and that other sources 
of immunoglobulins can be utiliZed. 
Preferably, the enZyme utiliZed cleaves the IgA, IgG and 
the IgM above the second disul?de bond (see FIG. 1). 
Accordingly, plant proteases such as papain, ?cin and bro 
melain are particularly useful enZymes for purposes of the 
method of the present invention. Other enZymes such as 
trypsin, chymotrypsin and pepsin fail to provide the desired 
cleavage above the second disul?de bond and, accordingly, 
are not appropriate for utiliZation in the present method. 
More particularly, the production of the desired peptides 
is completed in accordance With ultra?ltering With or With 
out dia?ltering techniques. Preferably, the source of immu 
noglobulins being treated With the enZyme is ultra?ltered 
through a polysulfone or other membrane having a molecu 
lar Weight cutoff of 10,000 Daltons. The permeate, that is, 
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the material passing through the membrane, comprises pep 
tides having a molecular Weight of less than 10,000 Daltons. 
Included in this are the carbohydrate moieties clipped from 
the light chains and variable regions of the IgA, IgG and IgM 
molecules. In fact, peptides having a molecular Weight of 
slightly greater than 1,000 Daltons have been found to 
provide the greatest inhibitory activity relative to the binding 
of immunoglobulins With antigen sites. Peptides smaller 
than 1,000 Daltons generally exhibit less activity and, 
therefore, are of little interest relative to the present method. 
As the peptide permeate is collected, an appropriate buffer 
(e.g. pasteuriZed skim milk) may be added to the source of 
immunoglobulins being treated With the enZyme. This is 
done volume-for-volume so that the original volume of the 
immunoglobulin source and enZyme (i.e. the retentate) is 
substantially maintained at a given level. 
The enZymatic treatment of the immunoglobulins is com 
pleted at any temperature Where enZymatic inactivation does 
not occur. HoWever, temperatures just beloW the enZyme’s 
point of denaturation are most ef?cient. Accordingly, for 
papain, ?cin and bromelain the enZymatic treatment is 
completed betWeen 30—50° C. and most preferably approxi 
mately 40° C. Further, the enZymatic treatment is completed 
for a relatively extended period of time of at least tWo hours. 
This alloWs the enZyme to hydroliZe signi?cant portions of 
the immune proteins IgA, IgG and IgM including the 
constant regions and carbohydrate moieties of the variable 
regions and light chains. Of course, as the small peptides are 
cleaved, they are Washed through the ultra?ltration mem 
brane as permeate. 
As indicated above, the permeate from the ultra?ltration 
comprises peptides of less than 10,000 Daltons and 
preferably, peptides of approximately 1,000 Daltons. Fol 
loWing collection, these may be concentrated utiliZing 
reverse osmosis or evaporation in accordance With proce 
dures Well knoWn in the art. These peptides may then be 
dried by using freeZe drying, spray drying, or vacuum drying 
techniques also Well knoWn to those skilled in the art. These 
dried preparations may then be subsequently formulated into 
usable preparations for any number of applications. 
In accordance With further aspects of the method for 
inhibiting the binding activity of mammalian 
immunoglobulins, the next step is the reacting of an immu 
nogen With the peptides produced and collected in the 
manner just described. These peptides then bind and block 
antigenic sites/determinants on the immunogens. This may 
be done in accordance With any number of Ways appropriate 
to achieve this purpose. For example, Where spermatoZoa 
are being treated for purposes of subsequent arti?cial 
insemination, the spermatoZoa may be diluted by adding an 
appropriate quantity of physiologically balanced sodium 
citrate solution maintained at an appropriate temperature to 
maintain the viability of the spermatoZoa. The inhibitory 
peptides are then added to the spermatoZoa solution Which 
may be suitably mixed by agitation for a period of approxi 
mately 15 minutes. 
FolloWing the reacting of the immunogen With the pep 
tides is the step of introducing the peptide bound and 
blocked immunogen (e.g. spermatoZoa) into the mammal. 
Since the antigenic sites are bound and blocked, the natural 
antibody defense netWork of the mammal is essentially 
prevented from reacting and attacking the immunogen. 
Accordingly, problematic immune reactions may be essen 
tially defeated. Thus, it should be appreciated that this 
invention has potentially unlimited applications in the health 
care ?eld Where problematic immune reactions might oth 
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erWise prevent a medical doctor or technician from com 
pleting treatment and achieving a desired result. For 
example, in the instance of arti?cial insemination, a greater 
number of spermatoZoa are maintained viable through inhi 
bition of the binding activity of the immunoglobulins of the 
female host. Accordingly, these spermatoZoa remain free to 
reach the ovum and complete the desired fertiliZation. 
In accordance With yet another aspect of the present 
invention a method is provided for inhibiting culture agglu 
tination in a fermentation medium including immunoglobu 
lins. As previously described, the method includes the initial 
step of treating a source of immunoglobulins With an 
enZyme (e. g. papain, ?cin and/or bromelain) to hydroliZe the 
immunoglobulins into peptides having a molecular Weight 
of less than 10,000 Daltons. The ultra?ltration and dia?l 
tration techniques already described are utiliZed for this 
purpose. Similarly, the collecting of the peptides and the 
concentrating and drying of the peptides for subsequent 
formulation into culture media preparations is also com 
pleted. These peptides, preferably, of approximately 1,000 
Daltons and incorporating carbohydrate moieties clipped 
from tips of the light chains or variable regions of IgA, IgG 
and IgM immune proteins function to inhibit the binding 
activity of immunoglobulins. 
The next step in the method of inhibiting culture agglu 
tination is the adding of the peptides to a groWth media for 
microorganisms useful in fermenting the fermentation 
medium. Speci?cally, the peptides are mixed With the 
groWth media at a Weight ratio of peptides to microorgan 
isms of at least substantially betWeen 0.05 to 1 and 0.2 to 1. 
Microorganisms are then added to and groWn in the inocu 
lated groWth media for a period of time of generally betWeen 
3 and 24 hours While maintaining the growth media Within 
a temperature range necessary to promote groWth and main 
tain the viability of the microorganisms. Preferably, some 
mixing is provided, such as With internal pH controlled 
groWth media through, for example, sloW agitation or other 
means. As the microorganisms groW in the inoculated 
groWth media, the peptides bind to antigenic sites or deter 
minants on the microorganisms. 
FolloWing groWth, the microorganisms may be used 
directly or recovered as, for example, by means of centrifu 
gation in a manner knoWn in the art. Next is the adding of 
the microorganisms groWn in the inoculated groWth media 
to the fermentation medium. There the microorganisms 
remain free to promote fermentation. Speci?cally, bound 
and blocked antigenic sites prevent immunoglobulins in the 
fermentation medium (e.g. Whey or milk culture) from 
binding With the microorganisms and agglutinating micro 
organisms to form long chains or clumps that entrap acid 
coagulated casein and settle to the bottom of the vat. 
As a result of the method of the present invention, 
agglutination is signi?cantly reduced and/or substantially 
eliminated. This results in an improved and more consistent 
distribution of microorganisms or starter culture throughout 
the fermentation medium and a more even acid production 
in the vat. Accordingly, product quality is more consistent 
and yield losses are reduced to the economic bene?t of the 
manufacturer. 
The folloWing example is presented to further illustrate 
the invention, but it is not to be considered as limited to. 
EXAMPLE 1 
Cultures: 
Frozen commercial Lactococcus lactis bulk starter cul 
tures OS, M30 and M37 (Rhone-Poulenc/Marschall Div., 
Madison, Wis.) Were inoculated (0.1 g) into 10 mL aliquot 
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of reconstituted NFDM (10% Wt/vol) Which had been ster 
ilized. The tubes Were incubated at 26° C. for approximately 
3 hours or until a curd Was formed. In the second propaga 
tion the formed curd Was transferred into 100 mL of steril 
ized NFDM (10% Wt/vol) and incubated for 18 hours. 10 
milliliters of the second propagation Was transferred into 
enzyme treated and control media, prepared as described 
beloW and incubated. 
Commercial cultures OS, M30 and M37 Were selected 
because of their sensitivities to agglutination. The OS cul 
ture is a cottage cheese culture Which does not normally 
agglutinate. This culture Was used as a control in the 
experimental design. Cultures M30 and M37 are cheddar 
cheese cultures that are extremely sensitive to agglutination. 
These tWo cultures represent a Worst case scenario if used in 
the manufacture of cottage cheese. 
Media Preparation: 
Rennet Whey Was treated With papain (Sigma Chemical 
Co., St. Louis, Mo.) While being ultra?ltered and dia?ltered 
using a holloW ?ber membrane (Supelco, Bellefonte, Pa.) 
With a molecular Weight cut-off of 10,000 Daltons. The 
process ran for 2 hours at 40° C. The permeate Was collected 
and freeze dried. The freeze dried permeate Was added (at 
41.7% level, dry Weight basis) to an internal pH control 
buffer salt mixture (as described in US. Pat. No. 4,402,986) 
(GalloWay West, Wis.) to replace the Whey. Acontrol media 
Was prepared using untreated Whey. Both media Were recon 
stituted (75.7 g/L) split into three fractions and heat treated 
at 85° C. for 45 minutes. The media Were cooled to 26° C. 
and inoculated With the test cultures and incubated at 26° C. 
for 16 hours or until pH 5.3 Was achieved. 
Monitoring Agglutination: 
Culture agglutination Was monitored by determining the 
pH differential in skim milk and by direct microscopic 
examination. Agglutination in skim milk Was monitored by 
inoculating the fermented media at a 5% level into pasteur 
ized (63° C., 30 minutes) skim milk contained in 1000 mL 
graduated cylinders and incubated at 32° C. The pH differ 
ential Was determined by measuring top and bottom pH of 
skim milk in the graduated cylinders at 1 hour intervals over 
5 hours. Recordings Were made 5 centimeters beloW the 
skim milk surface and at the bottom of the cylinder. A pH 
meter (American Scienti?c Products, McGaW Park, Ill.) Was 
equipped With an Orion combination pH electrode (Orion 
Research, Inc., Boston, Mass.). The electrode Was attached 
to a stainless steel rod, Which Was used to loWer the electrode 
to the bottom of the cylinder. A pH differential Was com 
puted by subtracting bottom pH from the top pH. 
At the end of 5 hours of incubation the bottom of the 
graduated cylinders Were visually inspected for sediment 
formation. Differences in total solids betWeen top and bot 
tom of the cottage cheese vats is a sensitive indicator of 
agglutination. Milk (or curd) samples Were taken from the 
bottom of the cylinders and stored at 4° C. overnight for 
direct microscopic examination the folloWing day. Next day 
samples Were gram stained in accordance With the procedure 
described in Wu, W. G. Ed. 1986. Stains and Media. Page 33, 
Medical Microbiology: ALaboratory Study. Star Publication 
Company, Bellemont Calif., in order to determine culture 
groWth characteristics and cells per chain distribution by 
microscopic examination. Photomicrographs (1000><) Were 
prepared to illustrate the differences in culture groWth 
characteristics, the extent of chain formation and clumping 
betWeen the cultures groWn in the tWo media. 
Statistical Analysis: 
The experiment Was replicated four times in a randomized 
complete block design. Data Was analyzed using the general 
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linear model procedure of Statistical Analysis System to 
determine differences betWeen media on agglutination. 
Least squares means and signi?cance of each treatment Were 
computed using Type IV sums of squares and predicted 
difference procedure. Least signi?cant differences Were 
computed for top and bottom pH differential. A pH differ 
ential betWeen top and bottom pH of 0.12 units or greater 
Was signi?cant (P<0.05). This pH differential Was used as an 
indicator of starter culture agglutination. 
Culture Performance: 
SloW or uneven acid production has been reported as an 
indicator of culture agglutination in previous studies. In this 
study acid production Was also used as an indicator of 
agglutination, thus an indicator of culture performance. 
Culture performance over the 5 hour incubation period in 
skim milk improved (P<0.01) for all three commercial 
cultures studied (OS, M30 and M37) When groWn in enzy 
mically treated Whey medium compared to the control 
(untreated Whey) medium (Table 1). 
TABLE 1 
Effect of enzymically treated Whey internal 
pH control media on rate of acid development 
in skim milk. 
Culture 
Media OS M30 M37 
Top pH 1. Control 5.251 6.23 6.22 
2. Enzyme 5.26 5.40 5.81 
treated 
Bottom 1. Control 5.10 5.55 5.57 
pH 2. Enzyme 5.17 5.08 5.63 
treated 
pH 1. Control 0.15 0.68 0.64 
diff.2 2. Enzyme 0.09 0.31 0.18 
treated 
1Least square means. Reps = 4 for all treatments, n = 20. A least square 
difference of 0.12 Was calculated When P = 0.05. 
2pH differential = top pH — bottom pH 
1Least square means. Reps=4 for all treatments, n=20. A least square 
difference of 0.12 Was calculated When P=0.05. 
2pH differential=top pH-bottom pH. 
The OS culture, Which is a mixed strain culture that 
infrequently agglutinates in agglutinin rich milk or under 
normal conditions, shoWed the least (P<0.01) amount of 
culture agglutination When groWn in the media. These 
results Were expected. The OS culture during the 5 hours of 
incubation had a faster rate of acid development (decrease in 
pH) (P<0.01) (see FIG. 2 and Table 1) and a smaller pH 
differential (P<0.01) (Table 1) than M30 and M37 cultures 
(see also FIGS. 3 and 4 and Table 1). Skim milk inoculated 
With OS culture groWn in control or enzymically treated 
media and incubated had a similar rate of acid production 
(rate of pH decrease) at the top and bottom of the graduated 
cylinders. The pH decreased steadily up to 4 hours of 
incubation and leveled off at pH 4.5 When the skim milk 
coagulated (FIG. 2). HoWever, over the 5 hour incubation 
period the pH differentials Were loWer for culture incubation 
enzymatically treated Whey medium suggesting that the 
performance of the OS culture Was improved by 40%. The 
pH differentials Were 0.15 and 0.09 for enzyme treated and 
control media, respectively (Table 1). When the skim milk 
cylinders Were visually inspected at the end of 5 hours, no 
visual sedimentation Was observed in either cylinder. 
When commercial M30 culture Was groWn in enzymically 
treated Whey medium and inoculated into skim milk con 
tained in graduated cylinders, rate of acid production at the 
top of the cylinder improved (P<0.01) over the 5 hour 
US 6,348,346 B1 
incubation period compared to the same culture grown in the 
control medium (see FIG. 3 and Table 1). In the cylinders 
inoculated With the M30 culture groWn in control media, top 
pH decreased only by 0.08 pH units over 5 hour period. This 
culture agglutinated Within the ?rst hour of incubation 
sinking to the bottom of the cylinders. Acid production at the 
bottom of the cylinders Was rapid as observed by rapid 
decline in bottom pH of the cylinders (FIG. 3). 
When the M30 culture Was groWn in the enZymically 
treated media and inoculated into skim milk, pH both at the 
top and at the bottom of the cylinders decreased at the same 
rate. The pH differential over 5 hour incubation period Was 
reduced from 0.68 (cultures groWn in the control medium) 
to 0.31 (that groWn in enZymically treated medium) (Table 
1). The pH differential Was decreased (P<0.01) by 55% 
suggesting that culture agglutination Was being inhibited 
and culture performance improved. 
Among all three commercial cultures studied, M37 
shoWed the greatest improvement: in culture performance 
When groWn in the enZyme treated Whey media compare to 
the control (Table 1 and FIG. 4). When M37 Was groWn in 
the control medium and inoculated into skim milk, the rate 
of acid production at the top of the cylinder Was sloW. The 
pH decreased by 0.06 units over 5 hours. Similar to the M30 
culture, M37 also agglutinated Within the ?rst hour of 
incubation falling to the bottom of the cylinders. The pH 
decrease at the bottom of the cylinders Was fairly rapid 
during the 5 hours of incubation (see FIG. 4). 
When the M37 culture Was groWn in the enZymically 
treated media and inoculated into skim milk a steady 
decrease in pH Was observed at the top and at the bottom of 
the cylinders over the 5 hours (see FIG. 4). The pH differ 
entials over the 5 hour incubation period decreased from 
0.64 for cultures groWn in the control medium to 0.18 to that 
groWn in enZymically treated medium (Table 1). The pH 
differential Was reduced (P<0.01) by 72% suggesting an 
inhibition of culture agglutination and improvement of cul 
ture performance. 
The cylinders Were visually inspected at the end of the 5 
hours for sediment formation. Cylinders inoculated With 
M30 and M37 cultures groWn in the control medium both 
had heavy sedimentation (5 and 6 cm deep, respectively) at 
the bottom of the cylinders. This sediment Was greatly 
reduced When M30 and M37 cultures Were groWn in the 
enZyme treated medium. A slight broWn tint on the color of 
the sediment Was also observed indicating that little addi 
tional casein from skim milk precipitated around the agglu 
tinated cell complexes. 
Statistical analysis shoWed media><culture interaction to 
be signi?cant (P<0.01) for rate of decrease of top and bottom 
pH and pH differentials. The extent that the culture perfor 
mance is improved When groWn in the enZymically treated 
Whey medium depends someWhat on the speci?c culture and 
perhaps is related to the severity of agglutination associated 
With a particular strain. The severity of agglutination of a 
particular strain depends on several factors such as the 
frequency that a speci?c antigenic determinant is expressed 
on the cell surface or the agglutinin titer Which may indicate 
an antibody’s speci?city to a certain cell surface antigenic 
determinant. Perhaps these factors contributed to the differ 
ences observed in this study and the extent of improvement 
in culture performance of the various commercial cultures 
investigated. 
Culture Morphology: 
When Lactococcus cultures agglutinate, long chains or 
clumps of chains are observed in the sediment formed, 
Whereas nonagglutinating cultures form smaller clumps or 
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no clumps and shorter chains appear more evenly dispersed 
throughout the skim milk. Photomicrographs of the three 
cultures groWn in the control medium and enZymically 
treated Whey medium shoWed that all three cultures formed 
considerable shorter chains and almost no clumping of 
chains When these cultures Were groWn in enZymically 
treated Whey medium compared to their controls. 
Short chains lacking in critical mass to sink to the bottom 
of the cylinders are more evenly dispersed throughout the 
skim milk providing for improved culture performance 
throughout the cylinder during incubation. Thus improved 
acid production particularly at the top of the cylinders Was 
observed. 
EXAMPLE 2 
The procedure set forth in Example 1 is folloWed except 
that non-fat dried milk is substituted for rennet Whey. 
EXAMPLE 3 
The procedure set forth in Example 1 is folloWed except 
that ?cin is substituted for papain. 
EXAMPLE 4 
The procedure set forth in Example 1 is folloWed except 
that raW Whey is substituted for rennet Whey. 
EXAMPLE 5 
The procedure set forth in Example 1 is folloWed except 
that bromelain is substituted for papain. 
EXAMPLE 6 
The procedure set forth in Example 1 is folloWed except 
that non-fat-dried milk is substituted for rennet Whey and 
?cin is substituted for papain. 
EXAMPLE 7 
The procedure set forth in Example 1 is folloWed except 
that raW Whey is substituted for rennet Whey and bromelain 
is substituted for papain. 
EXAMPLE 8 
Lactococcus lactis ssp. lactis B62 (Chr. Hansen 
Laboratories, MilWaukee, Wis.) Was propagated from froZen 
stock cultures in reconstituted (10%) nonfat dry milk. Insure 
Media (Waterford, Food Products) Was prepared (75.8 g/L 
distilled Water) and inoculated (4%) With the propagated 
culture and incubated at 26° C. overnight. 
Five hundred mL aliquots of Beef Plasma (4%) Were 
digested With crude Papain (1%), crude Ficin (0.1%) and 
crude Bromelain (0.01%) at 26° C. for 2 h. Digested Beef 
Plasma Was ultra?ltered (3000 mWco, Dia?o Ultra?ltration 
membranes, Amicon, Inc.) at 4° C. Permeates Were stored 
(—10° C.) until media Were formulated. 
Five Internal pH Controlled bulk starter media Were 
prepared. Media Were designed around a commercial lactic 
medium sold by Waterford Food Products Which supplied 
both an intact medium (InsureTM) and the buffering salts 
(InsureTM salts) used in their intact medium. TWo media 
Were prepared from InsureTM medium, one of Which Would 
be used in a treatment spiked With puri?ed immunoglobulin 
(1 g/250 mL). These tWo media Were used as controls. Three 
media Were prepared using the InsureTM salts (0.15 g) plus 
yeast extract (1%, amount normally in INSURETM medium) 
reconstituted With 5 mL of one of three enZyme hydrolyZed 
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permeates. All media Were heat treated at 85° C. for 45 min 
and stored at 4° C. A commercial single strain lactic culture 
B62 Was used to inoculate (50%) these media. All Were 
incubated (26 C) overnight to develop bulk starters. 
Nonfat dry milk (8.8%) Was reconstituted in distilled 
Water and placed in ?ve (250 mL) graduated glass cylinders. 
One g of freeze dried, puri?ed immunoglobulin protein Was 
added to one skim milk-containing cylinder. Control culture 
Was added to the cylinder containing the immunoglobulin. 
The other skim milk containing cylinders Were inoculated 
With the other bulk starters. All skim milks Were inoculated 
With 4% bulk starter. All skim milk-cylinders Were incu 
bated at 31° C. for 6 h. pH measurements Were determined 
after inoculation and at 1 h intervals. pH measurements Were 
taken at 5 cm beloW the surface and on the bottom of each 
cylinder. 
RESULTS 
A plot of the pH at the top of the skim milk column is 
shoWn in FIG. 5. As expected the skim milk containing the 
added immunoglobulin had the sloWest drop in pH. This is 
because the immunoglobulin enhances culture 
agglutination, that causes the cells to clump together and fall 
to the bottom of the cylinder. Since most of the culture Was 
on the bottom of the cylinder the acid development in the top 
of the skim milk column Was limited to the culture remain 
ing in solution. The skim milk containing the other control 
culture Was the second sloWest in developing acid in the top 
of the cylinder. Evidently, suf?cient immune proteins Were 
present in the skim milk to cause the culture to agglutinate 
and drop to the bottom of the cylinder. HoWever, not as 
many culture cells dropped in this skim milk as did in the 
skim milk that contained the added immunoglobulin. 
All three skim milk’s that Were inoculated With culture 
groWn in media that contained peptides developed acid in 
the top of the skim milk column faster (p<0.001) than the 
controls. Also note that the bulk starters that contained the 
peptides did not drop the initial pH of the skim milk as much 
as the control media. Evidently peptides derived from blood 
serum protected the culture from agglutinating and more of 
the culture remained in solution. Culture groWn in the 
medium containing peptides produced by papain appeared to 
be the most protected. The pH of this skim milk dropped 
faster than the skim milk that contained the cultures that 
Were groWn in the media containing the ?cin and bromelain 
peptides. 
The pH differentials (difference betWeen the top and 
bottom pH of the skim milk after four hours of incubation) 
is shoWn in Table 2. Differentials result When culture cells 
drop to the bottom of the cylinder. The lactic cells on the 
bottom are more numerous and therefore produce more acid 
than those throughout the body of the skim milk. Note that 
the cultures groWn in the media containing peptides had a 
loWer differential than the controls. 
TABLE 2 
Effect of culture media on pH differentials 
in skim milk after 4 h of incubation. 
Culture Medium pH differential 
Insure .51 
Insure + Immunoglobulin .56 
Insure salt + Ficin peptide .46 
Insure salt + Papain peptide .32 
Insure salt + Bromelain peptide .37 
It is evident from Examples 1—7 that culture agglutination 
protective blockers can be cut from milk sources or from 
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blood serum as shoWn in this example. Indeed any source of 
material that contains immunoglobulin may be used as a 
starting material to produces these peptides. 
EXAMPLE 9 
The procedure set forth in claim 8 is folloWed except that 
a puri?ed immune protein preparation is substituted for the 
digested beef plasma. 
EXAMPLE 10 
Often Women can not become pregnant because their 
immune system (immuno-proteins IgM, IgG and IgA) 
attacks the spermatoZoa. The Immuno-proteins bind to anti 
genic sites located on the surface of the sperm cell. These 
immuno-proteins also bind to each other (complimentary 
binding). As the immuno-proteins bind to antigenic sites on 
the sperm surface a conformation shift occurs alloWing 
complimentary binding to occur, thus chains of immune 
proteins form bridges betWeen sperm cells causing the cells 
to agglutinate. Agglutination inhibits spermatoZoa mobility, 
thus they are unable to travel far enough to ?nd and fertiliZe 
the female egg. The purpose of this project Was to ?nd a Way 
to inhibit spermatoZoa agglutination. 
Materials and Methods 
Preparation of peptide blockers. Peptide blockers Were 
prepared from sWeet Whey Which had been hydrolyZed With 
papain at 28° C. During the hydrolyZation process peptides 
Were collected by pumping the hydrolysate through a 10,000 
MW cut off polysulfone ultra?ltration membrane. Permeate 
from the membrane Was freeZe dried to concentrate the 
collected peptides. 
Preparation of blood serum. Bovine blood Was collected 
at the time of slaughter. The blood Was alloWed to coagulate 
While cooling to 2° C. Coagulated blood Was stirred and 
centrifuged at 5000><g for 10 min. Serum from each centri 
fuge tube Was carefully removed and stored in 1 and 2 ml 
cryo-vials. Cryovials Were froZen at —20° C. until the serum 
Was used. 
Preparation of spermatoZoa. Human spermatoZoa Were 
Washed in TEST buffer (1/1 ratio), centrifuged (50,000><g) 
and resuspended in TEST buffer to their original volume. A 
reaction mixture Was prepared from 5 ml of Washed 
spermatoZoa, With and Without 10 mg peptide blockers, and 
either 0.4 or 0.5 ml Bovine blood serum. SpermatoZoa Were 
monitored at 0,1, 5, 10, 15, 20, 25, 30 min. to determine the 
number of active cells, motility, and grade. 
Agglutination determination. SpermatoZoa from reaction 
mixtures Were placed (0.05 ml) on a Warmed (38° C.) slide 
and covered With a cover slip. The slide Was placed an a 
Warmed microscope table (38° C.) and vieWed at 100><. 
Slides (Ektachrome 5017, ASA 100) Were taken at all 
observations times. 
Total sperm cell numbers Were determined using direct 
microscopic observation techniques using a calibrated slide. 
Number of free cells Were determined from the slides by 
counting the free sperm cells that Were not in clumps. Total 
free sperm cell counts /ml Were then computed from the area 
ratio of the calibration slide. 
Mobility Was determined by a trained technician Who 
estimated the number of spermatoZoa that Were actually 
moving using a scale of 0 to 100. Grade of spermatoZoa 
(hoW Well they move) Was also determined by the same 
technician using a scale of 1 to 4. 
Results and Discussion 
Agglutination model. The model used to determine agglu 
tination of human sperm cells Was designed to cause the 
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spermatozoa to agglutinate Within a short time interval 
(approximately 10 min). This model Was considered to be an 
extremely harsh environment for normal sperm cells. Typi 
cally sperm cells Would not encounter this concentration of 
immuno-protein or blood serum. Also this model used a 
different sperm donor each day, therefore the variability 
betWeen sperm sources to agglutination Was considered to 
be maximiZed. 
Free spermatoZoa. More free cells of spermatoZoa Were 
observed (P<0.05) in samples containing peptide blockers 
than samples Which did not contain peptide blockers (FIG. 
6). Both blocked and unblocked spermatoZoa reaction mix 
tures started out With approximately 400><105 free sWim 
ming cells. Free sWimming cells decrease (P<0.0001) With 
time in both blocked and unblocked reactions. The reaction 
mixture containing peptide blockers averaged 300><105 free 
cells, While the sample Without peptide blockers averaged 
200><105 free sWimming cells, a difference of nearly 100>< 
105 cells/ml. After incubating the reaction mixtures for 10 
minutes, sperm cell agglutination abated and little neW 
sperm cell agglutination occurred When reaction mixtures 
contained 0.5 ml of blood serum. Sperm cell differentials 
betWeen blocked and unblocked reaction mixtures betWeen 
10 and 20 min averaged 70><105 cell/ml. 
SpermatoZoa mobility. Experiments observing spermato 
Zoa mobility Were conducted in reaction S mixtures con 
taining both 0.4 and 0.5 ml of blood serum. Results pre 
sented in FIG. 3, shoW that reaction mixtures containing 
peptide blockers had a greater mobility than those Without 
blockers. 
TABLE 3 
Time (min) 
TRTS 0 1 5 10 15 20 35 40 50 
Motility 
(‘70) 
W/PB 58 58 58 50 57 51 50 50 50 
W/O 50 48 48 37 40 10 5 5 5 
PB 
Control 70 70 70 70 70 70 70 70 70 
Grade 
(0—4) 
W/PB 3.5 3.5 3.5 3.3 3.3 3.3 3.3 3.2 3.0 
W/O 3.3 3.3 3.3 3.0 3.0 0 0 0 0 
PB 
Control 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
The results obtained in this study indicate that the pres 
ence of peptides blockers reduced the incidence of aggluti 
nation and higher numbers of “free” spermatoZoa exhibited 
levels of motility and grade of motility (P<0.05). Signi?cant 
agglutination occurred after 10 minutes of incubation. 
Conclusions: SpermatoZoa incubated With TEST media in 
the presence of peptide blockers Were immunoprotected 
from the immune proteins present in bovine blood serum. 
The qualative characteristics of these spermatoZoa suggest 
that peptide blockers can be a useful mode of immunopro 
tecting spermatoZoa during semen preparation and more 
importantly after the placement of the spermatoZoa inside 
the female reproductive tract. 
EXAMPLE 11 
Modulated differential scanning calorimetry (TA 
instruments, Model DSC 2920) Was performed to thermally 
analyZe Bovine IgG (reagent grade), hydrolyZed Whey pep 
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tides and lactose (anhydrous). Peptides Were separated from 
papain hydrolyZed Whey by ultra?ltration (10,000 mWco 
polysulfone membrane) and freeZe dried. Empty aluminum 
reference and sample pans Were paired to 10.5 mg. Samples 
Were Weighted (1.7 mg IgG, 4 mg peptide, 0.4 mg lactose) 
in the sample pan and skim milk ultra?ltrate buffer Was 
added by micro-pipette (to 100 pL volume). Samples Were 
dissolved by stirring With a micro-spatula. Sample and 
reference (empty) pans Were hermetically sealed. Calorim 
etry measurements Were conducted (30 to 150° C.) With 
modulation amplitude of 0.531° C./100 sec and ramp gra 
dient of 2° C./min. 
Thermal analysis of IgG revealed major heat ?oWs fol 
loWed non-reversing heat ?oWs by approximately 1° C. at 
peaks of 74, 104 and 119 to 123° C. Aheat capacity shift Was 
noted at 104° C. Minor non-reversing heat ?oWs occurred at 
48 to 49, 54 to 55 and 88 to 90° C. 
The freeZe dried fraction contained both lactose and 
peptides. Lactose produced extremely linear heat ?oW 
curves that did not appear to interfere With thermal analysis 
of the peptide fraction. Fractionated Whey peptides con 
tained 2 sulfur linkages that broke at peaks of 119 to 124° 
C. Other heat ?oW patterns from Whey peptides started and 
peaked at 46.0 and 51.8, respectively, and 87.9 and 942° C., 
respectively. These heat ?oWs appeared to align With tWo 
minor heat ?oW areas observed in IgG but not With the major 
heat ?oW area. Although modulated differential scanning 
calorimetry cannot be used to identify a parent molecule it 
can be used to identify disul?de bonds and structural char 
acteristics that are apparent in both molecules. This data is 
consistent and supports the observations that the active Whey 
peptide are derived from immue proteins such as IgG. 
In summary, numerous bene?ts have been described 
Which result from employing the concepts of the present 
invention. A novel method has been described that is par 
ticularly useful in inhibiting the binding activity of immu 
noglobulins for a particular immunogen. Speci?cally, the 
immunogen is treated With the inhibitor so as to block 
antigenic sites or determinants that otherWise Would be the 
target of immunoglobulin binding activity. Such a method 
ology has a number of applications and is useful in virtually 
all instances Where problematic immune reactions Would 
otherWise occur. Such applications include but are not 
limited to improving the ef?ciency and effectiveness of the 
cheese making process and arti?cial insemination tech 
niques While protecting the spermatoZoa from host antibody 
attack. 
The invention has been described herein With reference to 
certain preferred methods and binding activity inhibitors. 
HoWever, as it is obvious that variations thereon Will become 
apparent to those skilled in the art, the invention is not to be 
considered as limited thereto. 
What is claimed is: 
1. A method for inhibiting culture agglutination in a 
fermentation medium including immunoglobulins, compris 
ing the steps of: 
contacting an immunoglobulin selected from the group 
consisting of IgA, IgG, IgM and mixtures thereof With 
a plant protease selected from the group consisting of 
papain, ?cin, bromelain and mixtures thereof to hydro 
lyZe the immunoglobulin, thereby forming a composi 
tion comprised of immunoreactive peptides; 
submitting the composition comprising immunoreactive 
peptides to ultra?ltration and recovering and collecting 
immunoreactive peptides having a molecular Weight of 
less than 10,000 Daltons; 
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adding to a nutrient growth medium for a Lactococcus 
useful in a fermentation process an amount of the 
collected immunoreactive peptides of a molecular 
Weight of less than 10,000 Daltons effective to bind 
antigenic sites on the Lactococcus; 
innoculating said nutrient groWth medium With the Lac 
tococcus useful in a fermentation process and groWing 
said Lactococcus in the nutrient groWth medium until 
antigenic sites on the Lactococcus are bound and 
blocked With immunoreactive peptides of a molecular 
Weight of less than 10,000 Daltons; 
transferring the proliferated Lactococcus having antigenic 
sites blocked to a fermentation medium Wherein immu 
noglobulins comprised in the fermentation medium 
cannot bind the antigenic sites on the Lactococcus 
blocked by immunoreactive peptides of a molecular 
Weight of less than 10,000 Daltons; 
Whereby agglutination of the Lactococcus in the fermen 
tation medium is inhibited. 
2. The method as set forth in claim 1, Wherein said 
immunoreactive peptides have a molecular Weight of about 
1,000 Daltons. 
3. The method set forth in claim 1, Wherein said immu 
noglobulin is provided from a source selected from the 
group consisting of raW Whey, dried Whey, Whey protein 
isolates, non-fat-dried milk, blood serum protein isolates, 
puri?ed immune protein preparations and mixtures thereof. 
4. A method for inhibiting culture agglutination in a 
fermentation medium including immunoglobulins, compris 
ing the steps of: 
contacting an immunoglobulin selected from the group 
consisting of IgA, lgG, IgM and miXtures thereof With 
a plant protease selected from the group consisting of 
papain, ?cin, bromelain and mixtures thereof to hydro 
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lyZe the immunoglobulin, thereby forming a composi 
tion comprised of immunoreactive peptides; 
submitting the composition comprising immunoreactive 
peptides to dia?ltration and recovering and collecting 
immunoreactive peptides having a molecular Weight of 
less than 10,000 Daltons; 
adding to a nutrient groWth medium for a Lactococcus 
useful in a fermentation process an amount of the 
collected immunoreactive peptides of a molecular 
Weight of less than 10,000 Daltons effective to bind 
antigenic sites on the Lactococcus; innoculating said 
nutrient groWth medium With the Lactococcus useful in 
a fermentation process and groWing said Lactococcus 
in the nutrient groWth medium until antigenic sites on 
the Lactococcus are bound and blocked With immu 
noreactive peptides of a molecular Weight of less than 
10,000 Daltons; 
transferring the proliferated Lactococcus having antigenic 
sites blocked to a fermentation medium Wherein immu 
noglobulins comprised in the fermentation medium 
cannot bind the antigenic sites on the Lactococcus 
blocked by immunoreactive peptides of a molecular 
Weight of less than 10,000 Daltons; 
Whereby agglutination of the Lactococcus in the fermen 
tation medium is inhibited. 
5. The method as set forth in claim 4, including adding a 
buffer to the composition comprising immunoreactive pep 
tides at the same rate as the immunoreactive peptides are 
collected. 
6. The method as set forth in claim 4, Wherein the 
immunoglobulin is contacted With the plant protease at a 
temperature betWeen 30—50° C. for a period of time of at 
least tWo hours. 
